Fixed‐dose aspirin monotherapy compared with thromboelastography directed antiplatelet therapy in long‐term management of left ventricular assist devices. Issue 9 (24th May 2022)

• Record Type: Journal Article
• Authors: Fanelli, Sophia J.; Elzeneini, Mohammed; Meece, Lauren E.; Mahmoud, Ahmad; Jeng, Eric I.; Harris, Neil; Ahmed, Mustafa M.
• Is Part Of: Journal of cardiac surgery. Volume 37:Issue 9(2022)
• Page Start: 2621
• Page End: 2628
• Publication Date: 2022-05-24
• Subjects: antithrombotic agent -- aspirin -- heart failure -- platelets -- transplantation; Heart -- Surgery -- Periodicals; 617.412005
• DOI: 10.1111/jocs.16637
• Languages: English
• ISSNs: 0886-0440

Abstract

Abstract: Background and Aim: The role of thromboelastography (TEG) in managing antiplatelet therapy (APT) in left ventricular assist devices (LVADs) is controversial. Our aim was to determine whether removal of TEG from an LVAD‐specific APT protocol reduced late‐onset bleeding without increasing thromboembolic complications. Methods: We performed a single‐center, retrospective cohort study including all recipients of a continuous‐flow LVAD between April 2005 and November 2019 ( n = 293). LVAD recipients before June 1, 2017 ( n = 221) whose APT was monitored and adjusted using TEG were compared with LVAD recipients after June 1, 2017 ( n = 72) where TEG was not utilized. Occurrence of late‐onset bleeding events after postoperative Day 7 and thromboembolic events were collected. APT doses, warfarin use and International normalized ratio (INR) values were collected at discharge and at 1, 3, 6, and 12‐months postimplantation. Results: Over a median 12‐month follow‐up, INTERMACS major bleeding events occurred in 35% of patients where TEG was utilized compared with 29% where TEG was not utilized ( p = 0.375), and procedural intervention was required in 29% compared with 18%, respectively ( p = 0.058). Use of TEG was associated with higher doses of aspirin (>325 mg) (41% compared with none) and use of a second antiplatelet (dipyridamole) (43% compared to 1%). Despite this, there was no significant difference in thromboembolic events (15% in each). Conclusions: Our study suggests the use of TEG led to increased doses of aspirin as well as adding a second antiplatelet agent, without improving outcomes in LVAD recipients. Furthermore, the removal of TEG from an LVAD‐specific APT protocol did not worsen thromboembolic outcomes.